Showing results (661-670 of 763) with videos related to

Sort By:
Pageof 77
The New England Journal of Medicine|November 2, 2004
Preventing microalbuminuria in type 2 diabetesPiero Ruggenenti, Anna Fassi, Anelja Parvanova Ilieva, et al.
Lancet (London, England)|March 16, 2005
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trialPiero Ruggenenti, Annalisa Perna, Giacomina Loriga, et al.
Hypertension (Dallas, Tex. : 1979)|July 14, 2010
Monitoring initial response to Angiotensin-converting enzyme inhibitor-based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trialsKaty J L Bell, Andrew Hayen, Petra Macaskill, et al.
Scientific Reports|February 20, 2019
Urinary proteome signature of Renal Cysts and Diabetes syndrome in childrenPierbruno Ricci, Pedro Magalhães, Magdalena Krochmal, et al.
Kidney International|June 6, 2024
The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceMarina Vivarelli, Jonathan Barratt, Laurence H Beck, et al.
JCI Insight|August 10, 2023
A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndromeMarina Vivarelli, Manuela Colucci, Mattia Algeri, et al.
American Journal of Nephrology|November 3, 2025
Endothelin-1 and Cardio-Kidney Events among Patients with Chronic Kidney Disease, Diabetes, and AnemiaFinnian R Mc Causland, Brian L Claggett, Petr Jarolim, et al.
Diabetes|September 17, 2016
Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled TrialPiero Ruggenenti, Manuela Abbate, Barbara Ruggiero, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 31, 2010
Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trialPiero Ruggenenti, Annalisa Perna, Marcello Tonelli, et al.
Kidney International|March 4, 2011
A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosisHoward Trachtman, Fernando C Fervenza, Debbie S Gipson, et al.
Pageof 77